MX2022002339A - Derivados de alfa-d-galactopiranosido. - Google Patents
Derivados de alfa-d-galactopiranosido.Info
- Publication number
- MX2022002339A MX2022002339A MX2022002339A MX2022002339A MX2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A
- Authority
- MX
- Mexico
- Prior art keywords
- diyl
- formula
- galactopiranoside
- alpha
- derivatives
- Prior art date
Links
- -1 4,5-dihydroisoxazole-3,5-diyl Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019073063 | 2019-08-29 | ||
| PCT/EP2020/074121 WO2021038068A1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002339A true MX2022002339A (es) | 2022-04-06 |
Family
ID=72561746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002339A MX2022002339A (es) | 2019-08-29 | 2020-08-28 | Derivados de alfa-d-galactopiranosido. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12319672B2 (zh) |
| EP (1) | EP4021904B1 (zh) |
| JP (1) | JP7612669B2 (zh) |
| KR (1) | KR102824799B1 (zh) |
| CN (1) | CN114585619B (zh) |
| AU (1) | AU2020338816B2 (zh) |
| BR (1) | BR112022003562A2 (zh) |
| CA (1) | CA3148365A1 (zh) |
| ES (1) | ES2972551T3 (zh) |
| HR (1) | HRP20240297T1 (zh) |
| HU (1) | HUE066221T2 (zh) |
| IL (1) | IL290815B2 (zh) |
| MA (1) | MA57000B1 (zh) |
| MX (1) | MX2022002339A (zh) |
| MY (1) | MY207787A (zh) |
| PH (1) | PH12022550436A1 (zh) |
| PL (1) | PL4021904T3 (zh) |
| RS (1) | RS65294B1 (zh) |
| SA (1) | SA522431777B1 (zh) |
| TW (1) | TWI864085B (zh) |
| UA (1) | UA129205C2 (zh) |
| WO (1) | WO2021038068A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| KR102854071B1 (ko) | 2019-08-09 | 2025-09-02 | 이도르시아 파마슈티컬스 리미티드 | (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체 |
| BR112021026829A2 (pt) | 2019-08-15 | 2022-02-22 | Idorsia Pharmaceuticals Ltd | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos; doenças e distúrbios hepáticos; doenças e distúrbios cardiovasculares; doenças proliferativas celulares e cânceres; doenças e distúrbios inflamatórios e autoimunes; doenças e distúrbios do trato gastrointestinal; doenças e distúrbios pancreáticos; doenças e distúrbios associados à angiogênese anormal; doenças e distúrbios associados ao cérebro; dor neuropática e neuropatia periférica; doenças e distúrbios oculares; lesão renal aguda e doença renal crônica; doenças e distúrbios pulmonares intersticiais; ou rejeição ao transplante |
| MX2023004033A (es) | 2020-10-06 | 2023-04-27 | Idorsia Pharmaceuticals Ltd | Espiro derivados de alfa-d-galactopiranosidos. |
| KR20230104190A (ko) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| ES3032987T3 (en) | 2021-02-09 | 2025-07-29 | Idorsia Pharmaceuticals Ltd | Hydroxyheterocycloalkane-carbamoyl derivatives |
| US20240109930A1 (en) * | 2021-03-03 | 2024-04-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN104822382B9 (zh) | 2012-10-10 | 2019-01-18 | 卡莱克汀医疗有限公司 | 用于治疗糖尿病性肾病和相关疾病的半乳糖分支的糖类化合物 |
| IN2015DN02573A (zh) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| CN104955471A (zh) | 2012-11-15 | 2015-09-30 | 塔夫斯大学 | 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒 |
| CN113621005B (zh) * | 2015-01-30 | 2025-07-04 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| HRP20190853T1 (hr) | 2015-07-06 | 2019-06-28 | Gilead Sciences, Inc. | Cot modulatori i postupci za njihovu upotrebu |
| US10889610B2 (en) | 2016-07-12 | 2021-01-12 | Galecto Biotech Ab | Alpha-D-galactoside inhibitors of galectins |
| MX392945B (es) | 2017-05-12 | 2025-03-19 | Galectin Sciences Llc | Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. |
| EP3621975A1 (en) | 2017-05-12 | 2020-03-18 | Galectin Sciences, LLC | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| EP3707149A1 (en) | 2017-10-31 | 2020-09-16 | Galectin Sciences, LLC | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020078807A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Prodrug of galactoside inhibitors of galectins |
| CA3113956A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| JP7486484B2 (ja) | 2018-11-21 | 2024-05-17 | ガレクト バイオテック エービー | ガレクチンのα－Ｄ－ガラクトシド阻害剤 |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3141436A1 (en) | 2019-07-03 | 2021-01-07 | Fredrik Zetterberg | Novel galactoside inhibitor of galectins |
| CN114450282A (zh) | 2019-07-05 | 2022-05-06 | 格莱克特生物技术公司 | 半乳糖凝集素的新型半乳糖苷抑制剂 |
| KR102854071B1 (ko) | 2019-08-09 | 2025-09-02 | 이도르시아 파마슈티컬스 리미티드 | (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체 |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| BR112021026829A2 (pt) | 2019-08-15 | 2022-02-22 | Idorsia Pharmaceuticals Ltd | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos; doenças e distúrbios hepáticos; doenças e distúrbios cardiovasculares; doenças proliferativas celulares e cânceres; doenças e distúrbios inflamatórios e autoimunes; doenças e distúrbios do trato gastrointestinal; doenças e distúrbios pancreáticos; doenças e distúrbios associados à angiogênese anormal; doenças e distúrbios associados ao cérebro; dor neuropática e neuropatia periférica; doenças e distúrbios oculares; lesão renal aguda e doença renal crônica; doenças e distúrbios pulmonares intersticiais; ou rejeição ao transplante |
| MX2023004033A (es) | 2020-10-06 | 2023-04-27 | Idorsia Pharmaceuticals Ltd | Espiro derivados de alfa-d-galactopiranosidos. |
| KR20230104190A (ko) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| ES3032987T3 (en) | 2021-02-09 | 2025-07-29 | Idorsia Pharmaceuticals Ltd | Hydroxyheterocycloalkane-carbamoyl derivatives |
| US20240109930A1 (en) | 2021-03-03 | 2024-04-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2020
- 2020-08-28 KR KR1020227009790A patent/KR102824799B1/ko active Active
- 2020-08-28 EP EP20775188.4A patent/EP4021904B1/en active Active
- 2020-08-28 US US17/638,799 patent/US12319672B2/en active Active
- 2020-08-28 IL IL290815A patent/IL290815B2/en unknown
- 2020-08-28 CN CN202080060134.6A patent/CN114585619B/zh active Active
- 2020-08-28 JP JP2022512854A patent/JP7612669B2/ja active Active
- 2020-08-28 MA MA57000A patent/MA57000B1/fr unknown
- 2020-08-28 ES ES20775188T patent/ES2972551T3/es active Active
- 2020-08-28 AU AU2020338816A patent/AU2020338816B2/en active Active
- 2020-08-28 PH PH1/2022/550436A patent/PH12022550436A1/en unknown
- 2020-08-28 TW TW109129635A patent/TWI864085B/zh active
- 2020-08-28 CA CA3148365A patent/CA3148365A1/en active Pending
- 2020-08-28 PL PL20775188.4T patent/PL4021904T3/pl unknown
- 2020-08-28 MX MX2022002339A patent/MX2022002339A/es unknown
- 2020-08-28 MY MYPI2022001043A patent/MY207787A/en unknown
- 2020-08-28 BR BR112022003562A patent/BR112022003562A2/pt unknown
- 2020-08-28 UA UAA202201022A patent/UA129205C2/uk unknown
- 2020-08-28 WO PCT/EP2020/074121 patent/WO2021038068A1/en not_active Ceased
- 2020-08-28 HR HRP20240297TT patent/HRP20240297T1/hr unknown
- 2020-08-28 HU HUE20775188A patent/HUE066221T2/hu unknown
- 2020-08-28 RS RS20240319A patent/RS65294B1/sr unknown
-
2022
- 2022-02-27 SA SA522431777A patent/SA522431777B1/ar unknown
-
2025
- 2025-04-29 US US19/193,332 patent/US20250257056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114585619B (zh) | 2024-09-27 |
| AU2020338816A1 (en) | 2022-04-14 |
| EP4021904C0 (en) | 2024-01-03 |
| US20250257056A1 (en) | 2025-08-14 |
| US20220281855A1 (en) | 2022-09-08 |
| US12319672B2 (en) | 2025-06-03 |
| PL4021904T3 (pl) | 2024-05-13 |
| SA522431777B1 (ar) | 2024-04-30 |
| IL290815A (en) | 2022-04-01 |
| ES2972551T3 (es) | 2024-06-13 |
| HUE066221T2 (hu) | 2024-07-28 |
| CN114585619A (zh) | 2022-06-03 |
| WO2021038068A1 (en) | 2021-03-04 |
| EP4021904B1 (en) | 2024-01-03 |
| MY207787A (en) | 2025-03-19 |
| BR112022003562A2 (pt) | 2022-05-24 |
| MA57000B1 (fr) | 2024-03-29 |
| HRP20240297T1 (hr) | 2024-05-10 |
| JP2022546029A (ja) | 2022-11-02 |
| RS65294B1 (sr) | 2024-04-30 |
| TW202122092A (zh) | 2021-06-16 |
| KR102824799B1 (ko) | 2025-06-24 |
| KR20220053622A (ko) | 2022-04-29 |
| AU2020338816B2 (en) | 2026-01-08 |
| TWI864085B (zh) | 2024-12-01 |
| UA129205C2 (uk) | 2025-02-05 |
| IL290815B2 (en) | 2025-08-01 |
| EP4021904A1 (en) | 2022-07-06 |
| PH12022550436A1 (en) | 2022-12-19 |
| CA3148365A1 (en) | 2021-03-04 |
| IL290815B1 (en) | 2025-04-01 |
| JP7612669B2 (ja) | 2025-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002339A (es) | Derivados de alfa-d-galactopiranosido. | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
| UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| AR050536A1 (es) | Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| MX2022000598A (es) | Preparacion de compuestos antibacterianos. | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| CL2021003348A1 (es) | Derivados de piridin–3–ilo. | |
| DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CO4980875A1 (es) | Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas | |
| CL2023000970A1 (es) | Espiro derivados de alfa-d-galactopiranosidos | |
| AR124720A1 (es) | Derivados de pirazolamida | |
| CL2023001138A1 (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3 |